Vipin Garg, Ph.D., has served as the Chief Executive Officer and a member of the Neos Therapeutics, Inc., board of directors since October 2013, and was named our President in July 2014. Prior to joining Neos, Dr. Garg served as President, Chief Executive Officer and a director of Tranzyme Inc., now Ocera Therapeutics, Inc. (NASDAQ: OCRX) from September 2001 to July 2013. Dr. Garg has also served as Vice President of Operations and Business Development, and later Chief Operating Officer, of Apex Bioscience, Inc. from 1994 to 2000, as Vice President of Development at DNX Bio-Therapeutics, Inc , now part of Baxter, from 1992 to 1994, as Director of Technical Services and Marketing at Sepracor, Inc., now Dainippon Sumitomo Pharma, from 1989 to 1992, and as Manager, Contract Services at Bio-Response Inc. from 1986 to 1989. Dr. Garg has served on the board of North Carolina Biotechnology Center and on the Executive Committee of CED (formerly the Council for Entrepreneurial Development), and is the recipient of the Ernst Young Entrepreneur of the Year Award for the Carolinas Region in 2009. Dr. Garg received his Ph.D. in Biochemistry from the University of Adelaide, Australia, his M.Sc. from the Indian Agricultural Research Institute in New Delhi, India, and his B.Sc. from Meerut University, India.
Richard Eisenstadt has served as our Chief Financial Officer since May 2014. Prior to joining us, he served as Chief Financial Officer of ArborGen Inc. from June 2013 to May 2014, and as Vice President of Finance and Chief Financial Officer of Tranzyme, Inc. now Ocera Therapeutics, Inc. (NASDAQ: OCRX) from June 2003 to December 2012. He previously held financial leadership positions at Cogent Neuroscience, Inc. and Nimbus CD International, Inc. Mr. Eisenstadt received his M.B.A. from James Madison University and his B.A. in Economics from the University of North Carolina, Chapel Hill.
Thomas McDonnell has served as our Chief Commercial Officer since April 2015. Prior to joining us, Mr. McDonnell spent ten years with Shire (NASDAQ:SHPG), most recently as Vice President of U.S. Marketing in the Neuroscience Business Unit from December 2013 to March 2015. From August 2012 to November 2013, he was Vice President, General Manager of Adult Psychiatry at Shire. Previously, he held several commercial and marketing positions at Shire, including Senior Director, General Manager for Equasym XL, Senior Director of Marketing for Intuniv, Director of Marketing for Vyvanse, and Senior Product Manager for Adderall XR. From 1997 to 2005, he held various sales, sales management and marketing positions at Abbott Laboratories and Knoll Pharmaceuticals. Mr. McDonnell received his B.A. in Marketing from Muhlenberg College.
Dorothy Engelking has served as our Vice President of Regulatory Affairs since April 2010. Prior to joining us, Ms. Engelking served as Vice President of Kendle International, Inc. from July 2008 to July2009, Senior Vice President of Regulatory Affairs at Xanodyne Pharmaceutics, Inc. from March 2006 to July 2008, and as Vice President of Regulatory Affairs at Watson Pharmaceuticals Inc., now Actavis plc (NYSE: ACT) from January 1999 to March 2006. She received her B.S. in Chemistry and M.S. in Analytical Chemistry from South Dakota School of Mines and Technology, and holds a Regulatory Certificate from the Regulatory Affairs Professional Society.
Russ McMahen has 25 years of industry experience specializing in solids, liquids and suspensions. Mr. McMahen oversees the development of new products and technology. He is the co-inventor of DTRS ® , RDIM™, DVR™, DKP™, DPD™ and SLIC™ delivery technologies. At Neos, Mr. McMahen has held various positions including Vice President, Research Development, Executive Vice President of Operations and Vice President of Scientific Affairs. Prior to joining Neos, Mr. McMahen served at Zenith/Goldline Laboratories which was subsequently acquired by Ivax Pharmaceuticals. He has a Bachelor of Science degree in Chemical Engineering from Louisiana Tech University.
Margaret Cabano has 15 years of industry experience and leads all aspects of operations, supply chain and production including responsibilities for customer management, planning and project management. Prior to joining Neos, Ms. Cabano worked in operations and supply chain management for Adams Respiratory Therapeutics and Cardinal Health. Ms. Cabano holds an MBA in Operations Management Science and a Bachelor of Science in Supply Chain Logistics from the University of North Texas.
Asif Mughal has over 15 years of experience of increasing responsibility in QC/QA management and leadership. In his last two assignments for West-Ward Pharmaceuticals and EMD Chemicals (an affiliate of Merck), Mr. Mughal had international and domestic quality system responsibility. Mr. Mughal earned his Bachelor Degree in chemistry from Temple University.
Vincent Mair joined Neos in May of 2015 as Vice President of Commercial Operations. Mr. Mair has been in the pharmaceutical industry since 2000, responsible for growth strategy and business analytics. Prior to joining Neos he spent seven years with Shire (NASDAQ: SHPG), most recently as Senior Director of Global Commercial Insights and Analytics. From 2008 to 2012 he held various positions in commercial strategy and insights including Marketing Insights Lead for Intuniv and Head of Business Analytics and Forecasting for the Gastrointestinal Business Unit. Previous to Shire, he was with Endo Pharmaceuticals (NASDAQ: ENDP), Adolor Corporation now Merck (NYSE: MRK), and Bristol-Myers Squibb (NYSE: BMY). Mr. Mair received his B.S. in Management Information Systems from the LeBow College of Business at Drexel University.
Steven has served as our Vice President of Sales since August 2014. He previously served as a consultant for us from April 2014 to June 2014. Previously, Mr. Lutz served as the President and Chief Executive Officer of Praelia Pharmaceuticals, Inc. from October 2011 to March 2014. Mr. Lutz was a founder of Cornerstone Therapeutics, Inc., which was subsequently acquired by Chiesi, Inc., where he served as Executive Vice President of Operations and as President of its subsidiary, Aristos Pharmaceuticals, Inc., from July 2003 to September 2011. He received his B.A. from Moravian College in Bethlehem, PA.
Carolyn Sikes has more than 25 years of experience in medical affairs and global drug development. Prior to joining Neos in July, 2010, Dr. Sikes held various leadership roles at Pfizer Pharmaceuticals, Inc., and has worked in multiple therapeutic areas, including the development of therapeutics for depression, anxiety, post-traumatic stress disorder, Alzheimer’s disease, schizophrenia, epilepsy, pain and other central nervous system disorders. She has consulted with many small and large pharmaceutical companies in drug development, medical affairs, and compliance. She holds a PhD in Psychobiology/Neuroscience from Duke University and completed a post-doctoral fellowship in Psychoneuroendocrinology at Cornell University Medical College.